title: Guidelines for anti-emetic therapy: acute emesis.
abstract: Anti-emetic therapy has become integral to the management of patients with cancer. Goals related to complete emesis control include providing treatment that reduces hospitalisation and time in the ambulatory setting, care that is convenient for the patient and therapy that enhances patients' quality of life. A panel of clinical, health economic and basic scientists with expertise in various oncology disciplines reviewed published literature to develop evidence-based consensus guidelines for the prevention and treatment of chemotherapy-induced emesis. Currently, serotonin receptor antagonists and corticosteroids are the two categories of anti-emetics that are most effective, have the fewest side-effects and are convenient to use. These agents are recommended in combination for highly emetogenic chemotherapy regimens and as single agents or in combination for moderately to highly emetogenic chemotherapy. When possible, these agents may be given orally in single doses; current evidence does not support dose escalation for either category of anti-emetics. In special situations, such as the use of high-dose chemotherapy combination regimens, the most emetogenic component of the regimen should dictate the choice of anti-emetic. Appropriate anti-emetic use described in these guidelines represents both good medical practice and a sensible economic approach to care.
authors.affiliation: Clinic of BMT, Haematology and Oncology, Idar-Oberstein, Germany. office@bmt-center-io.de
authors.forename: A A
authors.initials: AA
authors.lastname: Fauser
authors.forename: M
authors.initials: M
authors.lastname: Fellhauer
authors.forename: M
authors.initials: M
authors.lastname: Hoffmann
authors.forename: H
authors.initials: H
authors.lastname: Link
authors.forename: G
authors.initials: G
authors.lastname: Schlimok
authors.forename: R J
authors.initials: RJ
authors.lastname: Gralla
mesh_terms: D000208:Acute Disease; D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D004338:Drug Combinations; D006801:Humans; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D004338:Drug Combinations